Arris other research news

ARRS (South San Francisco) announced at its annual shareholder meeting that APC 366-A, which is in trials in asthma in the U.K., has been shown in large animals to reduce or eliminate bronchoconstriction. The data will be presented at the Symposium on Immunoregulation of Asthma II in Quebec later this month. The studies show that the mast cell enzyme tryptase is implicated in asthma and possibly in other inflammatory conditions, the company said. ...